Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
Portfolio Pulse from Lara Goldstein
UK-based Small Pharma (OTCQB:DMTTF) has released findings from its Phase 1b study on the interaction of its DMT compound, SPL026, and selective serotonin reuptake inhibitors (SSRIs) for the treatment of major depressive disorder (MDD). The study found that SPL026 was well-tolerated by all 17 patients, with no serious adverse events reported. The treatment showed greater antidepressant effects in the SSRI cohort, suggesting enhanced efficacy when administered jointly with SSRIs. Small Pharma's CEO mentioned exploring these findings as part of the integrated DMT program with Cybin (NYSE:CYBN).
September 26, 2023 | 6:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin could potentially benefit from the positive results of Small Pharma's Phase 1b study as the companies are set to explore these findings as part of their integrated DMT program.
Cybin's association with Small Pharma and the positive results from the Phase 1b study could potentially boost investor confidence in Cybin's own DMT programs and its stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Small Pharma's successful Phase 1b study results could boost investor confidence in the company's DMT programs and potentially its stock price.
The positive results from the Phase 1b study indicate that Small Pharma's DMT compound, when administered with SSRIs, could be a promising treatment for MDD. This could lead to increased investor interest in the company and potentially a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100